The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Trend Is Expected For The Tumor Exosome Profiling Market From 2026 To 2030?

The market size for tumor-informed minimal residual disease (MRD) tests has experienced rapid growth in recent years. It is projected to increase from $1.14 billion in 2025 to $1.32 billion in 2026, at a compound annual growth rate (CAGR) of 15.6%. This historical expansion is linked to factors such as rising cancer prevalence, advancements in genetic sequencing, the demand for post-treatment monitoring, regulatory approvals for molecular diagnostics, and the adoption of PCR and NGS technologies.

The market for tumor-informed minimal residual disease (MRD) tests is anticipated to experience significant expansion over the upcoming years. This market is projected to reach a valuation of $2.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.8%. Factors contributing to this growth during the forecast timeframe include the rise of personalized medicine, AI-powered data analytics for MRD, increased oncology research, the creation of non-invasive diagnostic assays, and seamless integration with hospital IT systems. Key trends anticipated in the forecast period encompass personalized MRD monitoring, incorporation into clinical decision support systems, analysis of non-invasive samples, highly sensitive ctDNA detection, and predictive modeling for disease recurrence.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample_request?id=27247992&type=smp

Which Significant Factors Are Encouraging Growth In The Tumor Exosome Profiling Market?

The increasing occurrence of cancer is projected to propel the expansion of the tumor exosome profiling market in the future. Cancer constitutes a range of illnesses defined by the unchecked proliferation and division of irregular cells, capable of invading adjacent tissues and metastasizing throughout the body. This rise in cancer cases stems from unhealthy living habits, such as inadequate nutrition, insufficient exercise, tobacco use, and excessive alcohol intake, all of which heighten the likelihood of developing different forms of cancer. Tumor exosome profiling aids in combating cancer by facilitating early discovery, tracking the advancement of tumors, and informing customized treatment approaches via the examination of tumor-originating exosomes found in bodily fluids. As an illustration, the World Health Organization, an international body based in Switzerland focused on global health policy and public health endeavors, reported in February 2024 that more than 35 million new cancer diagnoses are anticipated by 2050, representing a 77% surge from the approximately 20 million cases recorded in 2022. Consequently, the increasing incidence of cancer is fueling the swift expansion of the tumor exosome profiling market.

What Are The Core Segment Classifications In The Tumor Exosome Profiling Market?

The tumor exosome profiling market covered in this report is segmented –

1) By Product Type: Kits And Reagents, Instruments, Software, Services

2) By Sample Type: Blood, Urine, Saliva, Other Sample Types

3) By Application: Cancer Diagnostics, Prognostics, Therapeutics, Research

4) By End-User: Hospitals And Clinics, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Kits And Reagents: Isolation Kits, Detection Kits, Quantification Kits, Labeling Reagents, Antibodies

2) By Instruments: Flow Cytometers, Nanoparticle Tracking Analyzers, Ultracentrifuges, Microfluidic Devices, Polymerase Chain Reaction Machines (PCR) Machines

3) By Software: Data Analysis Software, Visualization Software, Bioinformatics Platforms, Statistical Modeling Software, Exosome Tracking Software

4) By Services: Sample Preparation Services, Exosome Isolation Services, Molecular Profiling Services, Data Analysis Services, Custom Assay Development Services

Which Trends Are Affecting The Tumor Exosome Profiling Market Framework?

Major companies engaged in the tumor exosome profiling market are focusing on developing innovative solutions, such as exosome assays based on liquid biopsy, to enable early cancer detection and personalized therapy monitoring. A liquid biopsy–based exosome assay is a blood test designed to identify tiny vesicles called exosomes, which are released by tumor cells, thereby allowing doctors to detect and monitor cancer without the need for invasive tissue biopsies. For instance, in June 2024, Mercy BioAnalytics Inc., a US-based biotechnology company, partnered with University College London (UCL), a UK-based university, to launch the Mercy Halo Ovarian Cancer Screening Test, which is a next generation extracellular vesicle liquid biopsy developed to identify ovarian cancer in asymptomatic, postmenopausal women by detecting multiple co-localized cancer biomarkers on individual tumor-derived vesicles using a low volume blood sample and a quantitative polymerase chain reaction (qPCR) based read out, offering high sensitivity and specificity several years before clinical diagnosis.

Who Are The Key Market Participants In The Tumor Exosome Profiling Market?

Major companies operating in the tumor exosome profiling market are Thermo Fisher Scientific Inc., Lonza Group Ltd., NanoFCM Inc., QIAGEN N.V., Bio-Techne Corporation, Miltenyi Biotec B.V. And Co. KG, Aethlon Medical Inc., Cusabio Technology LLC, Norgen Biotek Corp., Kimera Labs Inc, Diagenode Inc., Creative Biolabs Inc, Izon Science Ltd., System Biosciences LLC, Mercy Bioanalytics Inc, MtoZ Biolab, Capital Biosciences Inc., ExoCan Healthcare Technologies Private Limited, INOVIQ Ltd, Codiak BioSciences Inc.

Access The Complete Tumor Exosome Profiling Market Report:

https://www.thebusinessresearchcompany.com/report/tumor-exosome-profiling-market-report

Which Region Accounts For The Highest Share Of The Tumor Exosome Profiling Market?

North America was the largest region in the tumor exosome profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor exosome profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Tumor Exosome Profiling Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample_request?id=27247992&type=smp

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.